Allergies in India: a study on medication compliance.
There are no studies in Indian literature on compliance to various medications for allergic diseases such as nasal sprays, inhalers, immunotherapy and antihistamines. This study was initiated to cover this lacuna. Eighty young patients suffering from asthma with rhinitis or urticaria between the age group of 10 and 40 years were included in this study. Compliance to medications was carefully observed using dose diaries for a period of one year. The data obtained revealed the highest compliance for sublingual immunotherapy (84.19%) and the lowest for a nasal spray (62.32%). The compliance for a dry powder inhaler was 69.31% and for fexofenadine tablets it was 71.78%. These figures are surprisingly low, especially since this study was conducted in a private clinic.
Shaikh
Wiqar A
WA
Allergy and Asthma Clinic, Mumbai 400007.
Shaikh
Shifa Wiqar
SW
D000293:Adolescent; D000328:Adult; D018926:Anti-Allergic Agents / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy* / Q000453:epidemiology / Q000276:immunology; D001993:Bronchodilator Agents / Q000627:therapeutic use*; D019819:Budesonide / Q000627:therapeutic use; D002648:Child; D004983:Ethanolamines / Q000627:therapeutic use; D005260:Female; D000068759:Formoterol Fumarate; D006801:Humans; D007073:Immunoglobulin E / Q000276:immunology; D007194:India / Q000453:epidemiology; D008297:Male; D010349:Patient Compliance; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy* / Q000453:epidemiology / Q000276:immunology; D012882:Skin Tests; D013147:Spirometry; D016593:Terfenadine / Q000031:analogs & derivatives / Q000627:therapeutic use; D016896:Treatment Outcome; D014581:Urticaria / Q000188:drug therapy* / Q000453:epidemiology / Q000276:immunology
D018926:Anti-Allergic Agents; D001993:Bronchodilator Agents; D004983:Ethanolamines; D007073:Immunoglobulin E; D019819:Budesonide; D016593:Terfenadine; C093230:fexofenadine; D000068759:Formoterol Fumarate